Medicine – Porphyria

Porphyrias are a group of uncommon metabolic disorders caused by abnormalities in the haem biosynthesis pathway. Most porphyrias result from inherited deficiency of a specific enzyme involved in haem production, leading to accumulation of particular haem precursors or porphyrins.

The clinical features depend on which intermediate accumulates and where it accumulates, so different porphyrias may predominantly cause acute neurovisceral symptoms, photosensitive skin disease, or both.

1. Haem Synthesis and Porphyria

Haem is synthesised through a multistep biochemical pathway occurring partly in the:

Mitochondria

and partly in the:

Cytoplasm.

Each step requires a specific enzyme.

A deficiency in one of these enzymes causes substances produced before the blocked step to accumulate.

Therefore:

ENZYME DEFECT → ACCUMULATION OF HAEM PRECURSORS → PORPHYRIA.

2. Porphyrins Versus Porphyrin Precursors

The original description of:

“Overproduction of intermediates – porphyrins”

is broadly correct but can be made more precise.

Depending on the particular porphyria, the accumulated substances may include:

5-Aminolaevulinic acid – ALA.

Porphobilinogen – PBG.

Porphyrinogens.

Porphyrins.

The acute neurological porphyrias are particularly associated with increased:

ALA and PBG.

3. Classification of Porphyrias

Porphyrias can be classified according to their major clinical presentation.

Acute porphyrias predominantly cause:

Neurovisceral attacks.

Cutaneous porphyrias predominantly cause:

Photosensitivity and skin lesions.

Some porphyrias can produce:

Both neurological and cutaneous manifestations.

4. Acute Intermittent Porphyria

One of the most important acute hepatic porphyrias is:

Acute intermittent porphyria – AIP.

It classically presents with recurrent attacks of:

Severe abdominal pain + neurological or psychiatric symptoms + autonomic disturbance.

A key feature is:

Absence of photosensitive skin disease.

5. Inheritance of AIP

AIP is inherited in an:

Autosomal dominant – AD

pattern.

However, clinical penetrance is:

Low.

This means that many people carrying the pathogenic variant never develop a clinical attack.

Therefore:

INHERITED MUTATION DOES NOT NECESSARILY MEAN SYMPTOMATIC DISEASE.

6. Enzyme Defect in AIP

The deficient enzyme is:

Porphobilinogen deaminase.

The modern enzyme name is:

Hydroxymethylbilane synthase – HMBS.

Therefore:

AIP = HMBS / PORPHOBILINOGEN DEAMINASE DEFICIENCY.

7. Site of AIP Abnormality

AIP is primarily a:

Hepatic porphyria.

Reduced HMBS activity increases production and accumulation of upstream haem precursors, especially:

ALA

and

PBG.

These compounds are responsible for much of the acute neurovisceral toxicity.

8. Severe Abdominal Pain

The most characteristic presenting symptom of an acute AIP attack is:

Severe abdominal pain.

The pain is often:

Diffuse.

It can be severe despite relatively few objective abdominal findings.

9. Abdominal Examination

A useful clinical clue is:

Severe abdominal pain with little or no peritoneal irritation.

The abdomen may be relatively soft despite intense pain.

This sometimes leads patients to undergo extensive surgical investigations before the correct diagnosis is recognised.

10. Nausea and Vomiting

Acute attacks commonly produce gastrointestinal symptoms such as:

Nausea.

Vomiting.

Constipation.

Abdominal distension may also occur.

Constipation is often more characteristic than diarrhoea.

11. Neuropsychiatric Features

AIP can produce a wide range of:

Neurological and psychiatric manifestations.

These include:

Anxiety.

Agitation.

Insomnia.

Depression.

Confusion.

Hallucinations.

Psychosis.

Seizures.

Therefore:

ABDOMINAL PAIN + PSYCHIATRIC/NEUROLOGICAL FEATURES → THINK ACUTE PORPHYRIA.

12. Autonomic Dysfunction

Acute porphyria commonly affects the:

Autonomic nervous system.

This explains several findings in the original notes.

Typical features include:

Tachycardia.

Hypertension.

Sweating.

Tremor.

Autonomic gastrointestinal disturbance.

13. Hypertension

Hypertension may occur during an acute attack because of:

Autonomic overactivity.

Blood pressure may fluctuate substantially during severe attacks.

Therefore:

ABDOMINAL PAIN + TACHYCARDIA + HYPERTENSION

is an important acute porphyria pattern.

14. Tachycardia

Persistent:

Sinus tachycardia

is common during acute attacks.

It reflects autonomic disturbance and may accompany:

Hypertension, anxiety and abdominal pain.

15. Motor Polyneuropathy

The original notes correctly include:

Motor polyneuropathy.

Severe attacks can produce a predominantly:

Motor axonal neuropathy.

Weakness often begins proximally and can progress rapidly.

16. Severe Neuromuscular Disease

Progressive neuropathy may cause:

Limb weakness.

Reduced reflexes.

Bulbar weakness.

Respiratory muscle weakness.

In severe cases:

Respiratory failure

can occur.

This makes severe acute porphyria potentially life-threatening.

17. Sensory Symptoms

Although motor abnormalities are often most striking, patients may also develop:

Neuropathic pain.

Paraesthesia.

Sensory abnormalities.

However, motor neuropathy is especially important in severe attacks.

18. Seizures

Seizures can occur during AIP.

They may result from:

Direct neurological involvement

or from metabolic disturbances such as:

Hyponatraemia.

Treatment requires caution because several traditional antiseizure medications can induce hepatic enzymes and potentially worsen porphyria.

19. Hyponatraemia

An important feature not included in the original notes is:

Hyponatraemia.

It is common in acute porphyria and may be severe.

Possible mechanisms include:

SIADH.

Vomiting.

Abnormal renal sodium handling.

20. Why Hyponatraemia Matters

Severe hyponatraemia can contribute to:

Confusion.

Seizures.

Reduced consciousness.

Therefore serum electrolytes should be checked during suspected acute attacks.

21. Urine Colour

During an acute attack, urinary porphyrin precursors may cause urine to become:

Reddish-brown or dark.

Fresh urine may not initially look very abnormal but can darken after exposure to:

Air and light.

This is a useful classical clue, although it is not present in every patient.

22. Absence of Photosensitivity in AIP

A very important feature of AIP is:

No characteristic photosensitive skin lesions.

Therefore:

AIP = ACUTE NEUROVISCERAL PORPHYRIA WITHOUT PHOTOSENSITIVITY.

Other porphyrias may cause both neurovisceral and cutaneous disease, but AIP typically does not.

23. Precipitating Factors

AIP attacks usually occur when hepatic haem synthesis is increased.

This increases activity of:

ALA synthase 1 – ALAS1,

the rate-limiting enzyme of hepatic haem synthesis.

When downstream HMBS activity is deficient, increasing pathway activity results in greater accumulation of:

ALA and PBG.

24. Hepatic Enzyme-Inducing Drugs

The original notes correctly state that attacks can be precipitated by:

Hepatic enzyme-inducing drugs.

These drugs increase hepatic haem demand and may stimulate:

ALAS1 activity.

Examples historically associated with acute porphyria include certain:

Barbiturates.

Older anticonvulsants.

Some hormones and other medications.

Because drug safety varies, suspected porphyria should prompt checking a dedicated porphyria drug-safety resource rather than relying only on memorised lists.

25. Other Precipitants

Other important triggers include:

Fasting.

Very low-calorie dieting.

Alcohol.

Infection.

Physiological stress.

Hormonal changes, particularly progesterone-related menstrual influences.

Therefore attacks may occur without exposure to a medication.

26. Why Fasting Triggers Porphyria

Carbohydrate restriction and fasting stimulate hepatic metabolic pathways that increase:

ALAS1 activity.

This increases haem precursor production.

Therefore prolonged fasting can precipitate:

Acute porphyric attacks.

27. Diagnosis During an Acute Attack

The most useful initial biochemical investigation during suspected AIP is measurement of:

Urinary porphobilinogen – PBG.

During an acute attack, urinary:

PBG is markedly elevated.

Urinary:

ALA

is also elevated.

28. Urine PBG

Therefore a classic diagnostic sequence is:

Severe unexplained abdominal pain + neurological/autonomic symptoms

↓

Measure urine PBG

↓

Markedly elevated PBG → strongly supports acute porphyria.

Additional biochemical and genetic testing can then define the specific porphyria.

29. Genetic Testing

Once biochemical evidence supports the diagnosis, genetic testing can identify a pathogenic variant in:

HMBS.

This can also assist:

Family counselling

and

Testing of relatives.

Because penetrance is low, finding a mutation does not necessarily mean the person will develop attacks.

30. Treatment of an Acute Attack

Management begins with:

Stopping potential precipitating drugs or other triggers.

The patient should also receive supportive treatment for:

Pain.

Vomiting.

Electrolyte abnormalities.

Hypertension.

Neurological complications.

31. Intravenous Haem

For significant acute attacks, treatment with intravenous:

Haem arginate or other appropriate haem preparations depending on region

suppresses hepatic:

ALAS1 activity.

This reduces production of:

ALA and PBG.

Therefore haem therapy directly targets the biochemical overactivity responsible for the attack.

32. Carbohydrate Administration

Carbohydrate loading, usually with:

Glucose,

can suppress hepatic ALAS1 to some degree.

It may be useful in:

Mild attacks

or while definitive haem therapy is being arranged.

However, significant attacks generally require more specific therapy.

33. Givosiran

For selected patients with recurrent acute hepatic porphyria, modern preventive therapy includes:

Givosiran.

This is an RNA-interference therapy that reduces hepatic:

ALAS1 expression.

It can reduce the frequency of recurrent attacks in appropriately selected patients.

34. Long-Term Management

Long-term management includes:

Avoiding unsafe drugs.

Avoiding prolonged fasting.

Maintaining adequate nutrition.

Managing hormonal triggers when relevant.

Educating the patient about early symptoms.

Patients with recurrent disease may require specialist porphyria management.

35. AIP – Note Form

Inheritance:

Autosomal dominant.

Low penetrance.

Enzyme deficiency:

Porphobilinogen deaminase.

Modern name:

Hydroxymethylbilane synthase – HMBS.

Accumulated precursors:

ALA.

PBG.

Main clinical pattern:

Severe abdominal pain.

Vomiting.

Constipation.

Neuropsychiatric symptoms.

Tachycardia.

Hypertension.

Motor neuropathy.

Possible seizures.

Possible hyponatraemia.

Skin findings:

No characteristic photosensitivity.

Triggers:

Porphyrinogenic drugs.

Fasting.

Alcohol.

Infection.

Stress.

Hormonal changes.

Diagnosis during attack:

Markedly increased urinary PBG ± ALA.

Treatment:

Remove trigger.

Supportive care.

Correct electrolytes.

IV haem for significant attacks.

Glucose in selected mild situations.

Givosiran for selected recurrent disease.

36. Important Corrections to the Original Notes

The original statement:

“Overproduction of intermediates – porphyrins”

is better expanded to:

ACCUMULATION OF HAEM PRECURSORS OR PORPHYRINS, DEPENDING ON THE ENZYME DEFECT.

In AIP, the especially important accumulated substances are:

ALA AND PBG.

The enzyme described as:

Porphobilinogen deaminase

is now commonly called:

HYDROXYMETHYLBILANE SYNTHASE – HMBS.

AIP is autosomal dominant, but:

PENETRANCE IS LOW.

Therefore many genetically affected individuals remain asymptomatic.

An important feature missing from the original list is:

HYPONATRAEMIA, sometimes related to SIADH.

Another high-yield distinction is:

AIP DOES NOT CHARACTERISTICALLY CAUSE PHOTOSENSITIVITY.

Key Clinical Pattern

The classic acute intermittent porphyria picture is:

SEVERE ABDOMINAL PAIN

plus

NEUROPSYCHIATRIC FEATURES

plus

AUTONOMIC DISTURBANCE – TACHYCARDIA/HYPERTENSION

±

MOTOR NEUROPATHY

±

HYPONATRAEMIA.

Think:

AIP = AUTOSOMAL DOMINANT HMBS DEFICIENCY → ↑ ALA + ↑ PBG.

And remember:

ABDOMINAL PAIN + PSYCHIATRIC/NEUROLOGICAL FEATURES + DARKENING URINE + NO PHOTOSENSITIVITY → THINK ACUTE INTERMITTENT PORPHYRIA.lick here to start customizing